Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer
Journal of Medicinal Chemistry · 13.07.2023 · 66 (13) · 8822-8843
DOI: 10.1021/acs.jmedchem.3c00405 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 29.06.2023. Verfasst von Xin Han und 20 weiteren Autor:innen. Beteiligte Einrichtung: The Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States. Hauptthemen laut MEDLINE: Receptors, Androgen, Prostatic Neoplasms. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, Proteovant Therapeutics Inc.
Abstract (Originalsprache)
We report the discovery of ARD-2051 as a potent and orally efficacious androgen receptor (AR) proteolysis-targeting chimera degrader. ARD-2051 achieves DC50 values of 0.6 nM and Dmax >90% in inducing AR protein degradation in both the LNCaP and VCaP prostate cancer cell lines, potently and effectively suppresses AR-regulated genes, and inhibits cancer cell growth. ARD-2051 achieves a good oral bioavailability and pharmacokinetic profile in mouse, rat, and dog. A single oral dose of ARD-2051 strongly reduces AR protein and suppresses AR-regulated gene expression in the VCaP xenograft tumor tissue in mice. Oral administration of ARD-2051 effectively inhibits VCaP tumor growth and causes no signs of toxicity in mice. ARD-2051 is a promising AR degrader for advanced preclinical development for the treatment of AR+ human cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Oncopia Therapeutics Inc, 2 West Liberty Blvd., Malvern, Pennsylvania 19355, United States.
- Department of Pharmacology, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States.
ORCID-Profile: Xin Han, Chong Qin, Tianfeng Xu, Chao-Yie Yang, Duxin Sun, Shaomeng Wang
Förderung
- NCI NIH HHS
- National Cancer Institute
- Proteovant Therapeutics Inc
Zitieren
APA
Han, X., Zhao, L., Xiang, W., Miao, B., Qin, C., Wang, M., Xu, T., McEachern, D., Lu, J., Wang, Y., Metwally, H., Yang, C. Y., Kirchhoff, P. D., Wang, L., Matvekas, A., Takyi-Williams, J., Wen, B., Sun, D., Ator, M., …, & Wang, S. (2023). Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer. Journal of Medicinal Chemistry, 66(13), 8822-8843. https://doi.org/10.1021/acs.jmedchem.3c00405
Vancouver
Han X, Zhao L, Xiang W, Miao B, Qin C, Wang M, et al. Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer. Journal of Medicinal Chemistry. 2023;66(13):8822-8843. doi:10.1021/acs.jmedchem.3c00405
BibTeX
@article{Han2023,
author = {Han, Xin and Zhao, Lijie and Xiang, Weiguo and Miao, Bukeyan and Qin, Chong and Wang, Mi and Xu, Tianfeng and McEachern, Donna and Lu, Jianfeng and Wang, Yu and Metwally, Hoda and Yang, Chao-Yie and Kirchhoff, Paul D and Wang, Lu and Matvekas, Aleksas and Takyi-Williams, John and Wen, Bo and Sun, Duxin and Ator, Mark and Mckean, Robert and Wang, Shaomeng},
title = {Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {13},
pages = {8822--8843},
doi = {10.1021/acs.jmedchem.3c00405}
}
EUVIMED